Psoriasis care: New and emerging pharmacologic trends

Journal of Cutaneous Medicine and Surgery

Volumn 14, Issue 3, 2010, Pages 119-129

  Papp, Kim A ^a   Carey, Wayne ^b  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b Siena Medical Research Corp   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ADALIMUMAB; BECOCALCIDIOL; BETAMETHASONE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; GOLIMUMAB; HYDROCORTISONE; INCB 018424; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 6; JANUS KINASE INHIBITOR; METHOTREXATE; PIMECROLIMUS; PLACEBO; SALICYLIC ACID; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VITAMIN D DERIVATIVE; VOCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ARTICLE; ATOPIC DERMATITIS; CANADA; CLINICAL TRIAL; CROHN DISEASE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; HUMAN; HYPERCALCEMIA; LONG TERM CARE; LOW DRUG DOSE; NEPHROTOXICITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SKIN IRRITATION; TERATOGENICITY; TH17 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG COMBINATION;

ANTIBODIES, MONOCLONAL; CALCINEURIN; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT-CENTERED CARE; PSORIASIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D; ANTIBODIES, MONOCLONAL, HUMANIZED; CALCINEURIN INHIBITORS;

EID: 77952894857     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2010.09039     Document Type: Article

References (81)

1. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. Available at: http://www.dermatology.ca/ psoriasisguidelines (accessed June 2009).
2. Health Canada. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/ hpfb-dgpsa/pdf/medeff/raptiva-3-hpc-cps-eng.pdf (accessed January 2010).
3. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674 (Pubitemid 351671883)
4. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684 (Pubitemid 351671884)
5. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006;20: 370-379
6. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003;4:221-224
7. Housman TS, McMichael AJ, Mellen BG, et al. Use of 0.12% betamethasone valerate foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmet Dermatol 2002; 15:27-30.
8. Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003;148:134-138 (Pubitemid 36114874)
9. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003;72:407-411 (Pubitemid 37550149)
10. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268-269 (Pubitemid 26260260)
11. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998;39:447-450 (Pubitemid 28417383)
12. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998;139:649-654 (Pubitemid 28474311)
13. Cassano N, Miracapillo A, Coviello C, et al. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Invest 2006;26:227-233
14. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205: 389-393 (Pubitemid 35356768)
15. Guenther L, Cambazard F, Van De Kerkhof PCM, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-323
16. Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004;209:308-313 (Pubitemid 39482622)
17. Van De Kerkhof PCM. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004;151: 663-668
18. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 1989;125:1647-1652 (Pubitemid 20060609)
19. Pinheiro N. Comparative effects of calcipotriol ointment (50mug/g) and 5%coal tar/2% allantoin/0.5%hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract 1997;51:16-19 (Pubitemid 27129544)
20. Plum LA, Prahl JM, Ma X, et al. Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci U S A 2004;101: 6900-6904 (Pubitemid 38596415)
21. Helfrich YR, Kang S, Hamilton TA, Voorhees JJ. Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study. Br J Dermatol 2007;157:369-374 (Pubitemid 47083870)
22. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-115 (Pubitemid 350298146)
23. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-726 (Pubitemid 46955730)
24. Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol 2006;5:251-254
25. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-542 (Pubitemid 39278071)
26. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-279
27. Gramlick A, Fossati G, Nesbitt AM. Neutralization of soluble and membrane tumor necrosis factor-a (TNF-a) by infliximab, adalimumab, or certolizumab pegol using p55 or p75 TNF-a receptor-specific bioassays. Gastroenterology 2006;130:A697.
28. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-818 (Pubitemid 41242673)
29. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-986
30. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999;141:283-291 (Pubitemid 29397997)
31. Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643-651 (Pubitemid 32249523)
32. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 2002;27:111-114 (Pubitemid 35033469)
33. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Investig Dermatol 2003;120:211-216 (Pubitemid 36513069)
34. Papp KA, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a phase 3, randomized, multicenter, double-blind, placebo-controlled study. Lancet 2008;371:1337-1342 (Pubitemid 351522314)
35. Gupta AK, Langley RG, Lynde C, et al. ISA247: quality of life results from a phase II, randomized, placebo-controlled study. J Cutan Med Surg 2008;12:268-275
36. Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008;216:133-136 (Pubitemid 351158578)
37. Vissers WH, van Vlijmen I, van Erp PE, et al. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol 2008;158:705-712
38. Geiger JM. Efficacy of acitretin in severe psoriasis. Skin Ther Lett 2003;8:1-3, 7.
39. Actavis Group PTC. Soriatane. Canadian Product Monograph, 2009.
40. Bovenschen HJ, Otero ME, Langewouters AM, et al. Oral retinoic acid metabolism blocking agent rambazole for plaque psoriasis: an immunohistochemical study. Br J Dermatol 2007;156:263-270
41. Verfaille CJ, Thissen CA, Bovenschen HJ, et al. Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007;21:1038-1046 (Pubitemid 47304603)
42. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203:2577-2587
43. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-130 (Pubitemid 38076484)
44. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204.
45. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129:2175-2183
46. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-3194
47. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129: 1339-1350
48. Piskin G, Tursen U, Sylva-Steenland RM, et al. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23. Exp Dermatol 2004;13:764-772
49. Griffiths CE, Menter A, Strober B, Fidelus-Gort R. A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol 2009;60:AB166.
50. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-207
51. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-B1. Expert Rev Dermatol 2007;2:69-78.
52. Chen Y, Langrish CL, McKenzie B, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006;116:1317-1326
53. Punwani N, Gottlieb A, Birnbaum J, Williams W. Efficacy and safety of topical INCB018424, a selective Janus kinase 1 & 2 (JAK 1&2) inhibitor in psoriasis. J Am Acad Dermatol 2009;60:AB176.
54. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003;14:158-165 (Pubitemid 37254628)
55. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606. (Pubitemid 44436647)
56. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-566 (Pubitemid 351239154)
57. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216
58. Mazzotti E, Picardi A, Sampogna F, et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003;149:318-322 (Pubitemid 37100258)
59. Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001;144:967-972
60. Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008;216:260-270 (Pubitemid 351416731)
61. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158:549-557 (Pubitemid 351239150)
62. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153: 1192-1199 (Pubitemid 41779576)
63. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008;159:704-710
64. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161-1168 (Pubitemid 43727400)
65. Tan JK. Challenges and solutions in selecting antipsoriatic agents. J Cutan Med Surg 2007;11 Suppl 1:S48-53.
66. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006;142:836-842
67. Markham T, Rogers S, Collins P. NarrowbandUV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003;139:325-328 (Pubitemid 36330579)
68. Wall AR, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998;139:1005-1011
69. Berth-Jones J, Chu AC, Dodd WA, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127:266-271
70. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-196
71. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-743
72. Molin L, Cutler TP, Helander I, et al. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997;136:89-93. (Pubitemid 27016181)
73. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31:755-759 (Pubitemid 24340746)
74. Scarpa C. Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid. Acta Derm Venereol Suppl (Stockh) 1994;186:47. (Pubitemid 24208149)
75. Crosti C, Finzi AF, Mian E, Scarpa C. Calcipotriol in psoriasis vulgaris: a controlled trial comparing betamethasone dipropionate + salicylic acid. Int J Dermatol 1997;36:537-539 (Pubitemid 27355970)
76. Kose O. Calcipotriol ointment vs clobetasol solution in scalp psoriasis [1]. J Dermatolog Treat 1997;8:287. (Pubitemid 28033807)
77. Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003;148:326-333 (Pubitemid 36278976)
78. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin- 12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495-521. (Pubitemid 28183374)
79. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-957 (Pubitemid 47300009)
80. Nestle FO, Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol 2004;123:xiv-v.
81. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-1675